ArticleFrontiers in microbiology2023
Clinical characteristics and outcomes of acute kidney injury in patients with severe fever with thrombocytopenia syndrome.
Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Predictive Value of Admission Renal Injury-Related Indicators for Fatal Outcomes in Patients with Severe Fever with Thrombocytopenia Syndrome.Current medical science · 2026Article
- Development and Validation of a Novel Predictive Model and Simplified Clinical Indicator for Mortality in Severe Fever with Thrombocytopenia Syndrome Patients.Infection and drug resistance · 2026Article
- A nomogram to predict respiratory failure development in severe fever with thrombocytopenia syndrome patients with pneumonia.Scientific reports · 2025Article
- A novel prognostic nomogram for elderly patients with severe fever with thrombocytopenia syndrome.BMC geriatrics · 2025Article
- Prediction of Mortality by Clinical Laboratory Parameters in Severe Fever with Thrombocytopenia Syndrome: A Meta-Analysis.Tropical medicine and infectious disease · 2025Review
- Lactate Dehydrogenase/Albumin to Urea Ratio: A Novel Prognostic Indicator for Adverse Outcomes in Patients With Severe Fever With Thrombocytopenia Syndrome.Journal of medical virology · 2025Article
- Intensive care unit-based mortality risk model construction for severe fever with thrombocytopenia syndrome patients: a retrospective study.BMC infectious diseases · 2025Article
- The Naples prognosis score as an independent predictor of sepsis-associated acute kidney injury: a retrospective cohort study.Frontiers in medicine · 2025Article
- Pathogen profile of co-infections and mortality determinants among patients with severe fever with thrombocytopenia syndrome.Frontiers in cellular and infection microbiology · 2025Article
- Acute kidney injury as a prognostic marker in severe fever with thrombocytopenia syndrome.Scientific reports · 2024Article
- Machine learning-based risk prediction of acute kidney disease and hospital mortality in older patients.Frontiers in medicine · 2024Article
- Red Blood Cell Distribution Width Predicts Mortality in Hospitalized Patients with Severe Fever with Thrombocytopenia Syndrome.Journal of inflammation research · 2024Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging zoonosis caused by a novel bunyavirus. Until recently, the SFTS related acute kidney injury (AKI) was largely unexplored. This study aimed to investigate the clinical characteristics and outcomes of AKI in patients with SFTS. Methods: The non-AKI and AKI groups were compared in terms of general characteristics, clinical features, laboratory parameters and cumulative survival rate. The independent risk factors for in-hospital mortality in patients with SFTS were analyzed by multivariate logistic regression to identify the population with poor prognosis. Results: A total of 208 consecutive patients diagnosed with SFTS were enrolled, including 153 (73.6%) patients in the non-AKI group and 55 (26.4%) patients in the AKI group. Compared with patients without AKI, patients with AKI were older and had a higher frequency of diabetes. Among these laboratory parameters, platelet count, albumin and fibrinogen levels of patients with AKI were identified to be significantly lower than those of patients without AKI, while ALT, AST, ALP, triglyceride, LDH, BUN, uric acid, creatine, Cys-C, β2-MG, potassium, AMY, lipase, CK-MB, TnI, BNP, APTT, thrombin time, D-dimer, CRP, IL-6, PCT and ESR levels were significantly higher in patients with AKI. A higher SFTS viral load was also detected in the AKI patients than in the non-AKI patients. The cumulative survival rates of patients at AKI stage 2 or 3 were significantly lower than those of patients without AKI or at AKI stage 1. However, there was no significant difference in the cumulative survival rates between patients without AKI and those with stage 1 AKI. Univariate and multivariate binary logistic regression analyses demonstrated that stage 2 or 3 AKI was an independent risk factor for in-hospital mortality in patients with SFTS. Conclusion: AKI is associated with poor outcomes in patients with SFTS, especially patients at AKI stage 2 or 3, who generally have high mortality. Our findings support the importance of early identification and timely treatment of AKI in patients with SFTS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.